Speech-Language Pathologists in Gloversville, NY Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Elizabeth M Bauer, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 E State St, Gloversville, NY 12078 Phone: 518-339-0338

Ms. Linda Daigle Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 E State St, Gloversville, NY 12078 Phone: 518-775-5455

Alexandria Chace, M.S.ED., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 234 Lincoln St, Gloversville, NY 12078 Phone: 518-775-5760

Lucianne Nicholas Batty, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 304 Noroboro Rd, Gloversville, NY 12078 Phone: 518-725-1412

Lexi M Drake, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 E State St, Gloversville, NY 12078 Phone: 518-775-5455

Mrs. Teresa Williams, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 E State St, Gloversville, NY 12078 Phone: 518-775-5458

Mrs. Lisa Robare Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 136 Clovercrest Dr, Gloversville, NY 12078 Phone: 518-752-5707

Elizabeth Mary Thompson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 E State St, Gloversville, NY 12078 Phone: 518-773-7931

News Archive

SAM Junctional Tourniquet gets FDA clearance to control difficult bleeds in the axilla area

SAM Medical Products is pleased to announce it has received 510(k) regulatory clearance from the FDA to add an additional indication of use to the SAM Junctional Tourniquet.

Growing crisis of antibiotic-resistant bacteria

Scientists, the federal government and the pharmaceutical industry must work together quickly to solve the growing crisis of antibiotic-resistant bacteria, a Virginia Commonwealth University infectious disease expert said in today's issue of The New England Journal of Medicine.

KRYSTEXXA development and treatment failure gout to be presented

Savient Pharmaceuticals, Inc. announced that five abstracts relating to KRYSTEXXA (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009.

Could smart vital sign monitoring provide an early warning system for hospitals?

Vital signs have been around for a long period of time. Taking the pulse is probably one of the oldest examinations that doctors have made to assess patients.

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

GE Healthcare Medical Diagnostics today announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.

Read more Medical News

› Verified 9 days ago